Prostate Cancer Radiation Therapeutics Market Size, Share & Industry Analysis, By Radioisotopes (Radium-223, Lutetium-177, and Others) By Type (Metastatic Castration-Resistant Prostate Cancer and Non-Metastatic Castration-Resistant Prostate Cancer), By End-User (Hospitals, Specialty Clinics, and Others), and Regional Forecast, 2025-2032

Last Updated: November 24, 2025 | Format: PDF | Report ID: FBI112713

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2024
Forecast Period	2025-2032
Historical Period	2019-2023
Growth Rate	CAGR of 28.8% from 2025-2032
Unit	Value (USD Billion)
Segmentation	By Radioisotope, Type, End-User, and Region
By Radioisotope	· Radium-223 · Lutetium-177 · Others
By Type	· Metastatic Castration-Resistant Prostate Cancer · Non-Metastatic Castration-Resistant Prostate Cancer
By End-User	· Hospitals · Specialty Clinics · Others
By Region	· North America (By Radioisotopes, Type, End-User, and Country) - U.S. - Canada · Europe (By Radioisotopes, Type, End-User, and Country/Sub-region) - Germany - U.K. - France - Spain - Italy - Rest of Europe · Asia Pacific (By Radioisotopes, Type, End-User, and Country/Sub-region) - China - Japan - India - Australia - Rest of Asia Pacific · Rest of the World (By Radioisotopes, Type, and End-User)